Comparative Pharmacology
Head-to-head clinical analysis: REMICADE versus SIMPONI ARIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REMICADE versus SIMPONI ARIA.
REMICADE vs SIMPONI ARIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Infliximab is a chimeric monoclonal IgG1 antibody that binds with high affinity to tumor necrosis factor alpha (TNFα), neutralizing its pro-inflammatory cytokine activity by preventing its interaction with p55 and p75 cell surface TNF receptors.
Golimumab is a human IgG1κ monoclonal antibody that binds to and neutralizes tumor necrosis factor alpha (TNF-α), preventing its interaction with p55 and p75 cell surface TNF receptors. This reduces pro-inflammatory cytokine production and immune cell activation.
5 mg/kg IV at weeks 0, 2, and 6, then every 8 weeks thereafter; for rheumatoid arthritis, may increase to 10 mg/kg every 8 weeks if needed.
2 mg/kg intravenous infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 7.7 to 9.5 days (range 7-12 days). The prolonged half-life supports every-8-week dosing; may be shorter in patients with high tumor burden or immunogenicity.
Terminal elimination half-life approximately 10-13 days (mean 12 days), allowing for every 2-week dosing after initial loading regimen.
Infliximab is eliminated primarily via the reticuloendothelial system. No significant renal or biliary excretion; less than 0.1% of dose excreted unchanged in urine. Clearance is mainly through proteolytic catabolism.
Primarily degraded into small peptides and amino acids via reticuloendothelial system; negligible renal (0.1%) and fecal (<1%) excretion; no significant biliary elimination.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor